Back to search

Article

Engineered AAV9 as <i>in vivo</i> gene delivery platform for the selective transduction of TME cell subsets

2025-06-14

Abstract excerpt

Precise in vivo gene delivery to specific cell types remains a significant challenge in gene therapy, particularly for cancer immunotherapy applications. Here, we rationally engineered AAV9 to become a modular, receptor-targeted vector for selective in vivo gene delivery. We first identified the N272A and W503A mutations as effective in ablating the native tropism of AAV9. Subsequently, designed ankyrin repeat p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
10f0935b-5b5b-521f-93e3-37398f8e6d51
DOI
10.1101/2025.06.11.658408
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Engineered AAV9 as <i>in vivo</i> gene delivery platform for the selective transduction of TME cell subsetsDOI 10.1101/2025.06.11.658408
Select a neighboring publication to make it the new centre.